Parkinson Hastalığında D Vitamini Düzeyinin Hastalık Şiddeti, Denge ve Düşme ile İlişkisi

Year 2022, Volume: 6 Issue: 3, 255 - 260, 25.12.2022

Merve Damla Korkmaz

https://doi.org/10.46332/aemj.1033448

Abstract

Amaç: Parkinson hastalığında serum D vitamini düzeyleri ile hastalık şiddeti, denge sorunları ve düşme ve düşme korkusu arasındaki ilişkiyi değerlendirmek.

Araçlar ve Yöntem: Bu çalışma retrospektif, kesitsel olarak tasarlandı. Çalışmaya 45-80 yaş arası Parkinson hastaları ile sağlıklı kontroller dahil edildi. Çalışmanın sonuç ölçütleri, serum 25(OH) D vitamini seviyeleri, Hoehn&Yahr Ölçeği (HY), Birleşik Parkinson Hastalığı Derecelendirme Ölçeği-III (BPHDÖ-III), Berg denge ölçeği (BDÖ), Tinetti testi (TT) ve Uluslararası Düşme Etkinliği Ölçeği (DEÖ-U) idi.

Bulgular: Çalışmaya Parkinson hastalığı(PH) olan yetmiş iki katılımcı ve altmış sağlıklı kontrol dahil edildi. Yaş ortalaması, PH grubunda 67.4±8.3 yıl, kontrol grubunda 61.1±8.5 yıl idi. Ortalama 25(OH) D vitamini düzeyi PH grubunda 17.8±8.2 ng/ml, kontrol grubunda ise 22.2±9.7 ng/ml idi. Gruplar arasında 25(OH) D vitamini düzeyleri açısından istatistiksel olarak anlamlı fark vardı (p=0.005). PH grubundaki katılımcılar HY ölçeğine göre iki gruba ayrıldı (Erken evre grubu: Evre 1-2; İleri Evre grubu: Evre 3-4). Ortalama 25(OH) D vitamini düzeyi erken evre grupta 18,6±7,8 ng/ml iken ileri evre grupta 16,5±8,8 ng/ml idi. Her iki grupta da istatistiksel olarak anlamlı fark saptanmadı (p=0.299). Pearson analiz sonuçlarına göre PH grubunda, 25(OH) D vitamini düzeyleri, HY evreleri, BDÖ, TT, DEÖ-U ve BPHDÖ-III arasında korelasyon yoktu (p>0.05).

Sonuç: PH'da serum D vitamini düzeyleri sağlıklı kontrollere göre daha düşüktü. Ancak PH'da serum D vitamini düzeyleri ile hastalık şiddeti, denge sorunu ve düşme korkusu arasında anlamlı bir ilişki bulunamadı.

Keywords

düşme korkusu, nörodejenerasyon, postural instability, vitamin D eksikliği

Supporting Institution

Destekleyen kurum bulunmamaktadır.

Project Number

Etik kurul no: KAEK/2021.11.287

The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease

Abstract

Purpose: To evaluate the relationship between serum vitamin D levels with disease severity, balance problems and fear of falling in Parkinson’s disease.

Materials and Methods: This was a retrospective, cross-sectional study. Participants with Parkinson’s disease and healthy controls aged 45-80 years were included in the study. The outcomes of the study were serum 25(OH) vitamin D levels, Hoehn&Yahr Scale, Unified Parkinson’s Disease Rating Scale-III, Berg balance scale, Tinetti test, and International Falls Efficacy Scale scores.

Results: Seventy-two participants with Parkinson’s disease and sixty healthy controls were included in the study. The mean 25(OH) vitamin D level was 17.8±8.2 ng/ml in the PD group, while it was 22.2±9.7 ng/ml in the control group. There was a statistically significant difference in terms of 25(OH) vitamin D levels between the groups (p=0.005). The participants in the PD group were divided into two groups according to the HY scale scores (Early-stage group: Stage 1-2; Advanced-Stage group: Stage 3-4). The mean 25(OH) vitamin D level was 18.6±7.8 ng/ml in the early-stage group, it was 16.5±8.8 ng/ml in the advanced-stage group. No statistically significant differences were identified in both groups (p=0.299). There was no correlation between 25(OH) vitamin D levels, HY stages, BBS, TT, FES-I, and UPDRS-III in PD group (p>0.05).

Conclusion: Vitamin D levels were lower in PD than that in healthy controls. However, no significant relationship was found between vitamin D levels and disease severity, balance problem, and fear of falling in PD.

Keywords

fear of falling, neurodegeneration, postural instability, vitamin D deficiency

Project Number

Etik kurul no: KAEK/2021.11.287

References

• 1. Peterson AL. A review of vitamin D and Parkinson's disease. Maturitas. 2014;78(1):40-44.
• 2. Fullard ME, Duda JE. A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms. Front Neurol. 2020;11:454.
• 3. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21-30.
• 4. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13(3):100-105.
• 5. Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res. 1991;28(1):110-114.
• 6. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015;98(2):240-245.
• 7. Rimmelzwaan LM, van Schoor NM, Lips P, Berendse HW, Eekhoff EM. Systematic Review of the Relationship between Vitamin D and Parkinson's Disease. J Parkinsons Dis. 2016;6(1):29-37.
• 8. Lv Z, Qi H, Wang L, et al. Vitamin D status and Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2014;35(11):1723-1730.
• 9. Larsson SC, Singleton AB, Nalls MA, Richards JB. No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study. Mov Disord. 2017;32(8):1249-1252.
• 10. Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson's disease-a pilot study. Mov Disord. 2013;28(8):1133-1137.
• 11. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315-322.
• 12. Sahin Alak ZY, Ates Bulut E, Dokuzlar O, Yavuz I, Soysal P, Isik AT. Long-term effects of vitamin D deficiency on gait and balance in the older adults. Clin Nutr. 2020;39(12):3756-3762.
• 13. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-1028.
• 14. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-47.
• 15. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738-750.
• 16. Berg K, Wood-Dauphinee S, Williams JI. The Balance Scale: reliability assessment with elderly residents and patients with an acute stroke. Scand J Rehabil Med. 1995;27(1):27-36.
• 17. Sahin F, Yilmaz F, Ozmaden A, Kotevolu N, Sahin T, Kuran B. Reliability and validity of the Turkish version of the Berg Balance Scale. J Geriatr Phys Ther. 2008;31(1):32-37.
• 18. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119-126.
• 19. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614-619.
• 20. Ulus Y, Durmus D, Akyol Y, Terzi Y, Bilgici A, Kuru O. Reliability and validity of the Turkish version of the Falls Efficacy Scale International (FES-I) in community-dwelling older persons. Arch Gerontol Geriatr. 2012;54(3):429-433.
• 21. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
• 22. Van den Bos F, Speelman AD, van Nimwegen M, et al. Bone mineral density and vitamin D status in Parkinson's disease patients. J Neurol. 2013;260(3): 754-760.
• 23. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol. 2011;68(3):314-319.
• 24. Wang J, Yang D, Yu Y, Shao G, Wang Q. Vitamin D and Sunlight Exposure in Newly-Diagnosed Parkinson's Disease. Nutrients. 2016;8(3):142.
• 25. Gökşenoğlu G, Topal K, Paker N, Buğdaycı D, Kesiktaş N. Vıtamin D defıciency and related factors in Ambulatory Patients with Mild To Moderate Parkinson's Disease. Turk Geriatri Derg. 2017;20(4): 289-295.
• 26. Fidan F, Alkan BM, Tosun A. Çağın pandemisi: D vitamini eksikliği ve yetersizliği. Turk J Osteoporos. 2014;20(2):71-74.
• 27. Çalış HT, Sütbeyaz ST, Sunkak S, et al. Parkinson Hastalarında D Vitamini Düzeyinin Osteoporotik Kırıklar ve Postür Bozukluğu ile İlişkilendirilmesi. Turk J Osteoporos. 2017;23:16-20.
• 28. Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat. Rev. Neurol. 2017;13(11):689-703.
• 29. Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017;173:313-316.
• 30. Bischoff-Ferrari HA. Vitamin D in geriatric patients. Internist (Berl). 2020;61(6):535-540.